echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > A Chinese research team has developed a malignant cancer inhibitor.

    A Chinese research team has developed a malignant cancer inhibitor.

    • Last Update: 2020-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network September 27th reporter 25 from the Chinese Academy of Sciences Hefei Research Institute was informed that the institute's researchers have developed a malignant cancer inhibitor.
    evaluation of drug effectiveness in animals showed that the tumor suppression rate (TGI) reached 96%.
    the results are now published online in the international journal Signal Transduction and Targeted Therapy.
    recently, Liu Qingsong, a researcher at the Institute of Health and Medical Technology of the Hefei Research Institute of the Chinese Academy of Sciences, and Liu Jing, a researcher in pharmacy, developed a new generation of highly selective, highly active BTK kinase inhibitor CHMFL-BTK-85 for B-cell non-Hodgkin's lymphoma.
    B-cell non-Hodgkin's lymphoma is a common malignant cancer with a incidence rate of 10-15 per 100,000, which increases with age and has a low survival rate.
    Bruton Tyrosine Kinase (BTK) is a non-subject tyrosine kinase, and numerous studies have shown that overexposed and active BTK kinase is one of the leading causes of this type of cancer.
    previous studies, the team has developed a range of BTK kinase inhibitors with independent intellectual property rights through drug design and high-volume screening.
    in order to further improve its activity, selectivity and pharmacy, the research team continued to develop CHMFL-BTK-85, a small molecule inhibitor with good medicinal ability, through structurally based drug design methods.
    at the protein and cellular levels showed that the inhibitor significantly reduced the inhibition of Immune cell-mediated ADCC compared to the listed BTK inhibitor Erudini.
    In the evaluation of drug effectiveness in animals, the inhibitor was able to significantly inhibit the growth of subsoculation transplant tumors in mice constructed by TMD8 cells at a dose of 100 mg/kg/day, and the tumor suppression rate (TGI) reached 96%, which significantly extended the survival time of animals in mouse intation tumor models constructed by REC-1 cells.
    current research team is conducting further preclinical drug evaluation of CHMFL-BTK-85 with a view to rapidly promoting the drug into industrial development.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.